Table 1.
Demographic and clinical characteristics of the 266 patients analyzed.
| Total | |
|---|---|
| Parameter | n = 266 |
| Sex (F), n (%) | 85 (32) |
| Age at HCC enrollment, years, median (range) | 73 (45–87) |
| Etiology (viral vs. others), n (%) | |
| Viral | 212 (80) |
| Others | 54 (20) |
| Dimension, mm, median (range) | 26.5 (12–150) |
| Diameter, n (%) | |
| ≥5 cm | 224 (84) |
| <5 cm | 42 (16) |
| Child–Pugh score, n (%) | |
| A | 215 (81) |
| B–C | 51 (19) |
| BCLC stage | |
| 0 (Very early) | 60 (23) |
| A (Early) | 206 (77) |
| HCC Grade 1 (1–2 vs. 3), n (%) | |
| 1–2 | 201 (85) |
| 3 | 36 (15) |
| PVT, n (%) | 42 (16) |
| Malignant PVT, n (%) | 37 (14) |
| Type of curative treatment, n (%) | |
| RFTA | 201 (76) |
| PEI | 48 (18) |
| Resection | 29 (11) |
| TACE/TAE 2 | 39 (15) |
| Type of curative treatment, n (%) | |
| AFP cut-offs | 91 (34) |
| ≥20 ng/mL | 31 (12) |
| ≥200 ng/mL | 21 (8) |
| ≥400 ng/mL | 15 (6) |
| ≥1000 ng/ml | |
| HCC recurrence, n (%) 3 | 116 (44) |
| Local recurrence after treatment | 41 (15) |
| New intrahepatic | 77 (29) |
| Extrahepatic metastases | 28 (11) |
| Dead at f-up end, n (%) | 212 (80) |
| Disease-related death, n (%) | 157 (59) |
| Follow-up time, months, median (range) | 41.5 (1–174) |
1 Available for 237 patients; 2 always in combination with RFTA or PEI; 3 some patients experienced more than one type of HCC recurrence; AFP: alpha-fetoprotein; BCLC: Barcellona Clinic Liver Cancer; HCC: hepatocellular carcinoma; PVT: portal vein thrombosis; RFTA: radiofrequency thermal ablation; PEI: percutaneous ethanol injection; TACE: transcatheter arterial chemoembolization; TAE: transarterial chemoembolization.